Çмú ³í¹® - ¿¹¹æ ¹× ¹é½Å
ÁÖ¿ä ¹é½Å ÀÓ»ó ³í¹®µé
1. Pfizer/BioNTech (BNT162b1 and BNT162b2, mRNA vaccine)
(1) Phase 1/2
- NEJM 2020;383:2439-2450. December 17, 2020, https://doi.org/10.1056/NEJMoa2027906
- Nature 2020 Oct;586(7830):589-593 https://doi.org/10.1038/s41586-020-2639-4
(2) BNT162b2 (Efficienty and safety in an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial)
- NEJM. Online published. December 10, 2020
- https://doi.org/10.1056/NEJMoa203457
2. Moderna (mRNA-1273 vaccine)
(1) Preclinical (Nonhuman Primates)
- NEJM 2020;383:1544-1555. October 15, 2020
- https://www.nejm.org/doi/10.1056/NEJMoa2024671
(2) Phase 1
- NEJM 2020;383:1920-1931. November 12, 2020
- https://doi.org/10.1056/NEJMoa2022483
(3) Older adults ´ë»ó phase 1 - 56 to 70 years or ≥71 years, 4ÁÖ °£°ÝÀ¸·Î 25 μg or 100 μg Åõ¿©
- NEJM 2020;383:2427-2438, December 17, 2020
- https://doi.org/10.1056/NEJMoa2028436
3. AstraZeneca (Chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19)
(1) Phase 1/2
- Lancet 2020; 396: 467–78. July 20, 2020
- https://doi.org/10.1016/S0140-6736(20)31604-4
(2) Phase 2/3
- Lancet. Published Online November 19, 2020
- https://doi.org/10.1016/S0140-6736(20)32466-1
(3) Interim analysis of ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa
- Lancet. Published Online December 8, 2020
- https://doi.org/10.1016/S0140-6736(20)32661-1
4. Sinovac Life Sciences (CoronaVac, rAd5 vectored vaccine )
(1) Phase 1
- Lancet 2020;395:1845–54. May 22, 2020
- https://doi.org/10.1016/S0140-6736(20)31208-3
(2) Phase 2
- Lancet 2020;396:479–88. July 20, 2020
- https://doi.org/10.1016/S0140-6736(20)31605-6
(3) Phase 1/2
- Lancet Infect Dis 2020. Published Online November 17, 2020
- https://doi.org/10.1016/S1473-3099(20)30843-4
5. Novavax (NVX-CoV2373: rSARS-CoV-2 spike protein nanoparticle vaccine)
(1) Phase 1/2
- NEJM 2020;383:2320-2332. December 10, 2020
- https://doi.org/10.1056/NEJMoa2026920
6. BBIBP-CorV (National Program on Key Research Project of China)
(1) Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protectio against SARS-CoV-2
- Cell 2020:182,713–721, August 6, 2020
- https://doi.org/10.1016/j.cell.2020.06.008
(2) Phase 1/2
- Lancet Infect Dis 2020 Published Online October 15, 2020
- https://doi.org/10.1016/S1473-3099(20)30831-8
7. Ministry of Health of the Russian Federation (rAd26- and rAd5-spike glycoprotein
vaccine)
(1) Phase 1/2
- Lancet 2020;396: 887–97. September 4, 2020
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext
- Next ÁÖ¿ä ¹é½Å ÀÓ»ó ³í¹®µé(Updated at 2020.1.29)
- Previous Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (The Lancet Infectious Disease, Published: November 17, 2020)